Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Medical Genetics

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Genetic causes of Parkinson’s disease in the Maltese: a study of selected mutations in LRRK2, MTHFR, QDPR and SPR

  • Charmaine Zahra1,
  • Christine Tabone2,
  • Graziella Camilleri2,
  • Alex E. Felice1,
  • Rosienne Farrugia2 and
  • Stephanie Bezzina Wettinger1, 2Email author
BMC Medical GeneticsBMC series – open, inclusive and trusted201617:65

https://doi.org/10.1186/s12881-016-0327-x

Received: 4 July 2015

Accepted: 27 August 2016

Published: 9 September 2016

Abstract

Background

Mutations in Leucine-rich repeat kinase 2 NM_198578 (LRRK2 c.6055G > A (p.G2019S), LRRK2 c.4321C > G (p.R1441G)) and alpha-synuclein NM_000345 (SNCA c.209G > A (p.A53T)) genes causing Parkinson’s disease (PD) are common in Mediterranean populations. Variants in the Quinoid Dihydropteridine Reductase NM_000320 (QDPR c.68G > A (p.G23D)), Sepiapterin Reductase NM_003124 (SPR c.596-2A > G) and Methylenetetrahydrofolate Reductase NM_005957 (MTHFR c.677C > T and c.1298A > C) genes are frequent in Malta and potential candidates for PD.

Methods

178 cases and 402 control samples from Malta collected as part of the Geoparkinson project were genotyped for MTHFR polymorphisms, QDPR and SPR mutations. Only PD and parkinsonism cases were tested for SNCA and LRRK2 mutations.

Results

LRRK2 c.4321C > G and SNCA c.209G > A were not detected. The LRRK2 c.6055G > A mutation was found in 3.1 % of Maltese PD cases. The QDPR mutation was found in both cases and controls and did not increase risk for PD. The SPR mutation was found in controls only. The odds ratios for MTHFR polymorphisms were not elevated.

Conclusions

The LRRK2 c.6055G > A is a cause of PD in the Maltese, whilst QDPR c.68G > A, SPR c.596-2A > G and MTHFR c.677C > T and c.1298A > C are not important determinants of PD.

Keywords

Quinoid Dihydropteridine ReductaseSepiapterin ReductaseMethylenetetrahydrofolate ReductaseLeucine-rich repeat kinase 2Alpha-synucleinParkinson’s DiseaseMaltese

Background

Parkinson’s disease (PD) is a neurodegenerative disorder characterised by motor and non-motor symptoms and loss of dopaminergic neurons. A number of candidate genes were investigated to uncover the PD causing mutations in the Maltese population. Mutations in leucine-rich repeat kinase 2 NM_198578 (LRRK2) and alpha-synuclein NM_000345 (SNCA) genes have been associated with PD. Three mutations in these genes, namely LRRK2 c.6055G > A, LRRK2 c.4321C > G and SNCA c.209G > A are pathogenic mutations found in Mediterranean populations [1]. The Quinoid Dihydropteridine Reductase NM_000320 (QDPR) c.68G > A mutation and Sepiapterin Reductase NM_003124 (SPR) c.596-2A > G splice variant, are autosomal recessive mutations known to cause dihydropteridine reductase (DHPR) deficiency and Dopa-Responsive Dystonia (DRD) respectively in the Maltese with a high carrier frequency compared to other populations [2]. Catecholamine synthesis in patients is impaired as tetrahydrobiopterin (BH4), an essential cofactor of aromatic amino acid hydroxylases, is not produced in sufficient amounts as a result of these mutations [3]. SR is involved in de novo BH4 synthesis whilst DHPR is involved in recycling of the reduced cofactor [4]. It has been suggested that the SPR gene is the PARK3 locus implicated in sporadic PD [1] and decreased activity of DHPR due to low biopterin levels causes PD [5]. DHPR deficiency and DRD and PD have symptoms in common. The latter is characterized by childhood-onset dystonia responding well to low doses of L-Dopa. Gait and posture abnormalities are observed as the legs are primarily affected with diurnal fluctuation. Symptoms of parkinsonism (PS) are common. DHPR deficiency also presents with tonic disorders, abnormal movements, psychomotor retardation, hypersalivation and drooling, swallowing difficulties, hyperthermia [3, 6]. There is evidence that both the SPR and QDPR genes are good candidates to test for associations for PD.

MTHFR reduces folate and is involved in the production of S-adenosylmethionine which plays a role in dopamine (DA) synthesis and metabolism [7]. Defective MTHFR enzyme due to MTHFR NM_005957 c.1298A > C and c.677C > T has a lower activity and may result in elevated homocysteine levels, found to be relatively high in sera of PD patients [7, 8]. An indirect connection between the BH4 and folate pathways has been postulated [9]. The MTHFR c.677C > T TT genotype is found at a frequency of 9.1 % in Maltese newborn [10]. The mutant allele frequency for the MTHFR c.1298A > C was reported to be 23.2 % [11].

The objective of this study was to establish whether known pathogenic mutations (LRRK2 c.6055G > A, LRRK2 c.4321C > G and SNCA c.209G > A) are present in Maltese PD and PS cases, and to determine whether the functional MTHFR c.677C > T and c.1298A > C, QDPR c.68G > A and SPR c.596-2A > G genetic variants alter susceptibility to PD. This is the first time these genes have been tested for involvement in PD in the Maltese population.

Methods

Altogether 178 cases and 402 controls (Table 1) from Malta were collected as part of the FP5 EU-funded Geoparkinson project [12, 13]. The collection and testing were approved by the Research Ethics Committee of the University of Malta, Approval Numbers 53/2002 and 52/2008. All participants gave written informed consent.
Table 1

Characteristics of the population studied

Characteristics

Cases (N = 178)

Controls (N = 402)

Mean age (range)

72.9 (41–91)

74.3 (41–95)

Mean age of diagnosisa

66.3 (35–90)

 

Males

110 (61.8 %)

224 (55.7 %)

Females

68 (39.2 %)

178 (44.3 %)

Parkinson’s Disease

118

 

Parkinsonism

60

 

% Parkinsonism

33.70 %

 

Smokersd

61 (34.3 %)

177 (44.0 %)

Ever knocked unconsciouse

33b (18.6 %)

48 (11.9 %)

Family history of Parkinson’s diseasee

35 (19.7 %)

16c (4.0 %)

Use of pesticidese

27 (15.2 %)

42 (10.4 %)

aOut of 135 cases for which this data was available

bOut of 177 cases

cOut of 401 controls

dAssociated with decreased risk for PD and PS

eAssociated with increased risk for PD and PS

Cases were classified as having PD or PS using the United Kingdom Parkinson’s Disease Society Brain Bank clinical diagnostic criteria. Controls did not have PD or PS and were recruited from the community and from the bleeding room at St Luke’s Hospital which served many outpatient departments.

Genotyping of the QDPR c.68G > A, SPR c.596-2A > G [2], MTHFR c.677C > T [14], LRRK2 c.6055G > A [15], LRRK2 c.4321C > G [16] and SNCA c.209G > A [17] was performed as described previously. Genotyping of the MTHFR c.1298A > C was done using the 5’ exonuclease assay [18]. Cases and controls were genotyped for the QDPR c.68G > A, SPR c.596-2A > G mutations and the MTHFR c.677C > T and c.1298A > C polymorphisms. Genotyping for the LRRK2 c.6055G > A, LRRK2 c.4321C > G and SNCA c.209G > A was limited to cases since these are known PD-causing mutations [1].

DNA of 79 controls and 27 cases collected as part of the Geoparkinson project had been used up. These were mainly buccal samples. Additionally the PCRs did not work in a few samples.

Data Analysis: Allele frequencies were calculated. The genotypes in controls, when available, were tested for conformity with the Hardy-Weinberg Equilibrium (HWE). Both the crude and adjusted odds ratios (ORs) were calculated and the 95 % confidence intervals (CI) were derived from the logistic regression model.

Results

Four cases were heterozygous for the LRRK2 c.6055G > A mutation, giving an allele frequency of 1.4 % in PD and PS cases. This frequency was 3.1 % in PD cases alone. All were males with no family history of disease. Data for age at diagnosis was only available for two cases, one with PD and one with PS, both diagnosed at 65 years of age. None of the cases had the LRRK2 c.4321C > G or SNCA c.209G > A mutations. The frequencies obtained for the variants studied are presented in Tables 2 and 3.
Table 2

Allele Frequencies for the variants studied

Mutation/polymorphism

Allele frequencies in %

 

Controls (n mutant/total n)a

Cases (n mutant/total n)a

QDPR c.68G > A

0.3 (2/612)

0.3 (1/300)

SPR c.596-2A > G

0.7 (4/594)

0.0 (0/296)

MTHFR c.677C > T

34.7 (216/622)

33.8 (102/302)

MTHFR c.1298A > C

35.9 (225/626)

37.7 (114/302)

Tested in cases only

LRRK2 c.6055G > A

-

1.4 (4/292)

LRRK2 c.4321C > G

-

0.0 (0/296)

SNCA c.209G > A

-

0.0 (0/292)

n = number of alleles

aDNA of 79 controls and 27 cases had been used up and were therefore not available and a few samples did not yield PCR products

Table 3

Genotype Frequencies for MTHFR, all cases (PD & PS)

Polymorphism

Genotype frequencies

p-value

MTHFR c.677C > T

MTHFR c.1298A > C

No. of Cases (%)a

No. of Controls (%)a

Age-adjusted OR (95 % CI)b

 

CC

 

66 (43.7)

136 (43.7)

1

 

CT

 

68 (45.0)

134 (43.1)

1.0 (0.7–1.6)

0.8

TT

 

17 (11.3)

41 (13.2)

0.9 (0.5–1.6)

0.6

 

AA

60 (39.7)

132 (42.2)

1

 
 

AC

68 (45.0)

137 (43.8)

1.1 (0.7–1.7)

0.7

 

CC

23 (15.2)

44 (14.1)

1.2 (0.6–2.1)

0.6

CC

AA

16 (10.6)

24 (7.7)

1

 

CT

AC

41 (27.2)

67 (21.6)

0.9 (0.4–2.0)

0.8

TT

CC

-

-

-

 

CC

AC

27 (17.9)

69 (22.3)

0.6 (0.3–1.3)

0.2

CC

CC

23 (15.2)

43 (13.9)

0.8 (0.4–1.8)

0.6

CT

AA

27 (17.9)

66 (21.3)

0.6 (0.3–1.3)

0.2

CT

CC

-

-

-

 

TT

AA

17 (11.3)

41 (13.2)

0.6 (0.3–1.5)

0.3

TT

AC

-

-

-

 

aDNA of 79 controls and 27 cases had been used up and were therefore not available and a few samples did not yield PCR products

b p-values were all >0.05

Odds ratios for combined PD and PS cases were OR 0.9 (95 % CI 0.5–1.6) for the MTHFR 677 TT and 1.2 (95 % CI 0.6–2.1) for the MTHFR 1298 CC genotypes respectively. The results did not change materially after restricting to cases with PD or PS (see Additional file 1). No deviations from HWE were observed.

The allele frequency for QDPR c.68G > A was 0.3 % in both cases and controls. Two controls and one case were heterozygous for QDPR c.68G > A. One control was a 73 year old male whilst the other control was a 66 year old female. The case identified fulfilled the criteria for PD. She was 53 years of age when diagnosed and was also heterozygous for the MTHFR c.1298A > C polymorphism. None had a family history of PD.

Four individuals were identified as carriers of SPR c.596-2A > G, all of which were controls giving an allele frequency of 0.7 %. One was female aged 70, whilst the others were all men with ages of 79, 49 and 66.

Discussion

The known disease-causing LRRK2 c.6055G > A mutation was detected in PD cases whereas the LRRK2 c.4321C > G and SNCA c.209G > A mutations were not detected. The allele frequency of QDPR c.68G > A was the same in the cases and the controls whilst SPR c.596-2A > G was not detected in cases. The MTHFR c.677C > T and MTHFR c.1298A > C polymorphisms were not associated with PD in this study.

Four cases were heterozygous for the LRRK2 c.6055G > A mutation giving an allele frequency of 1.4 % in PD and PS cases or 3.1 % in PD cases alone. LRRK2 (c.4321C > G and c.6055G > A) mutations cause amino acid changes within the GTPase and/or kinase domains respectively which may signify an enzymatic change and thus mediate LRRK2 pathogenesis [19, 20]. The frequency of LRRK2 c.6055G > A was estimated to be 1 % of patients with sporadic PD and 4 % of patients with hereditary PD in other populations, with the highest frequencies occurring in Arabs and Jews but is rare in Asia [21]. This may be explained by differences in descent and founder effects [22]. The frequency of this mutation in Maltese PD patients, 3.1 %, is similar to that in the Spanish, Italians and Sardinians [21]. This is the first report of this mutation being found in the Maltese.

The LRRK2 c.4321C > G is common in the Basque population [23, 24]. The SNCA c.209G > A mutation is thought to have arisen from a common founder with Mediterranean ancestry [25, 26]. The results of the present study indicate that the LRRK2 c.4321C > G and SNCA c.209G > A mutations are very rare or completely absent in the Maltese population.

The allele frequencies for the QDPR c.68G > A and SPR c.596-2A > G we observed in controls (0.3 % and 0.7 % respectively) are much lower than those reported previously (3.3 % and 4.6 % tested on 272 and 87 newborns respectively) [2]. Therefore, we tested the population frequency in a larger number of Maltese newborn and observed allele frequencies of 0.64 %, and 1.3 % for the QDPR and SPR polymorphisms respectively (N = 475 and 315 respectively). These mutations are not a major cause of PD in the Maltese.

MTHFR was not a contributor to PD. The genotype frequencies obtained for the MTHFR c.677C > T are 43.7 % CC, 43.1 % CT and 13.2 % TT which are comparable to others reported for Maltese newborn [10, 27]. In contrast, the mutant allele frequency for the MTHFR c.1298A > C was somewhat higher than that observed previously in Maltese newborn (35.9 % vs. 23.2 % [11]). This suggests that there is no clear effect of these SNPs on PD probably due to the complex pathways involved.

The c.677C > T and c.1298A > C prevalence and frequencies vary considerably with ethnicities and geography [7]. While some studies have reported a lack of association between MTHFR polymorphisms and PD [28], others [29] reported a higher frequency of the MTHFR 677 TT genotype in PD patients and controls.

The MTHFR c.667C > T dimorphism causes hyperhomocysteimia in folate deficient individuals [30]. Homozygous mutants for MTHFR c.1298A > C have a lower enzyme activity than homozygous wildtype [7]. It is possible that the Maltese diet includes sufficient folate levels. In fact only 1.5 % of adult Maltese women and 3.1 % of adult Maltese men had low serum folate levels in a group of population controls and 1.5 % of women and 1.2 % of men had low serum Vitamin B12 levels (N = 137 and N = 326 for women and men respectively; Attard R and Bezzina Wettinger S, unpublished observations). The chance of being heterozygous or homozygous for these polymorphisms with low folate status is therefore very low. It should be noted that higher nutrient intake (folate and B vitamins) did not lower PD risk in a previous study [31]. It cannot be excluded that these polymorphisms have an effect in populations or individuals with low folate and Vitamin B12 levels.

This study had 80 % power to detect a 2-fold increase in risk for the MTHFR polymorphisms (35 % allele frequency), a 5-fold increased risk for SPR c.596-2A > G (0.7 % allele frequency) and an 8-fold increased risk for QDPR c.68G > A (0.3 % allele frequency) assuming a dominant model and for the MTHFR polymorphisms the sample size was sufficient to detect a two-fold increase in risk even for a recessive model assuming up to a 5 % Type I error rate. Thus the study is sufficiently powered to exclude a strong effect on PD risk of the SPR and QDPR mutations, and even 2-fold or more increase in risk due to the MTHFR mutations.

Conclusion

The LRRK2 c.6055G > A mutation accounts for 3.1 % of PD in the Maltese population. As LRRK2 c.6055G > A exhibits low penetrance and is found occasionally in controls [21], testing for LRRK2 c.6055G > A may be performed on patients and relatives who wish to ascertain the presence of a genetic defect. Testing for LRRK2 c.4321C > G and SNCA c.209G > A are not recommended as a first line of genetic testing in Maltese PD patients. There is no evidence to support involvement of DHPR and SR in PD, at least alone. One cannot exclude that they have a weak effect and even possibly an interaction when found together with other mild mutations. The absence of the LRRK2 c.4321C > G and SNCA c.209G > A could be a result of historical bottlenecks, and there may be some founder mutation in the Maltese that may explain familial cases that has not yet been tested for.

Abbreviations

BH4

Tetrahydrobiopterin

CI: 

Confidence intervals

DA: 

Dopamine

DHPR: 

Dihydropteridine reductase

DRD: 

Dopa-Responsive Dystonia

HWE: 

Hardy-Weinberg Equilibrium

L-Dopa: 

Levodopa

LRRK2: 

Leucine-rich repeat kinase 2

MTHFR: 

Methylenetetrahydrofolate Reductase

OR: 

Odds ratios

PD: 

Parkinson’s disease

PS: 

Parkinsonism

QDPR: 

Quinoid Dihydropteridine Reductase

SNCA: 

Alpha-synuclein

SNP: 

Single Nucleotide Polymorphism

SPR: 

Sepiapterin Reductase

Declarations

Acknowledgments

The samples and data used in this study were collected as part of the 5th framework (FP5) EU funded Geoparkinson study, project number QLK4‐CT‐1999‐01133. The Maltese arm of this group included Prof Christian Scerri, Dr Joseph Borg, Dr Karen Cassar, Ms Wilma Cassar, Ms Ruth Galdies, Dr Norbert Vella, Dr Vicky Mifsud, Dr Josanne Aquilina and Dr Galea Debono.

Funding

The samples and data used in this study were collected as part of the 5th framework (FP5) EU funded Geoparkinson study, project number QLK4‐CT‐1999‐01133. This work was supported by research grants of SBW and RF from the University of Malta. The funders played no other part in the research or its interpretation.

Availability of data and material

Complete crosstabs were included to allow replication of calculations. Any further information can be made available on request to the corresponding author.

Authors’ contributions

CZ was responsible for the execution of the research project, performed the statistical analysis and writing of the first draft. CT was responsible for the execution and analysis of the QDPR population testing. GC was responsible for the execution and analysis of the SPR testing. AEF was a reviewer and critique of the research project and the manuscript. RF designed and analyzed the research project concerning the newborn population studies. SBW designed, organized, reviewed and critically analyzed the research project and statistical analysis and was a reviewer and critique of the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The collection and testing were approved by the Research Ethics Committee of the University of Malta, Approval Numbers 53/2002 and 52/2008. All participants gave written informed consent.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Laboratory of Molecular Genetics, Department of Physiology and Biochemistry, University of Malta
(2)
Department of Applied Biomedical Science, Faculty of Health Sciences, University of Malta

References

  1. Gasser T. Mendelian forms of Parkinson’s disease. Biochim Biophys Acta. 2009;1792(7):587–96.View ArticlePubMedGoogle Scholar
  2. Farrugia R, Scerri CA, Montalto SA, Parascandolo R, Neville BGR, Felice AE. Molecular genetics of tetrahydrobiopterin (BH4) deficiency in the Maltese population. Mol Genet Metab. 2007;90(3):277–83.View ArticlePubMedGoogle Scholar
  3. Blau N, Thony B, Cotton RGH, Hyland K. Disorders of tetrahydrobiopterin and related biogenic amines. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Vogelstein B, Eds. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill; 2001. p. 1275–776.Google Scholar
  4. Thöny B. Tetrahydrobiopterin and its function. In: Blau N, editor. PKU and BH4: Advances in Phenylketonuria and Tetrahydrobiopterin Research. Heilbronn: SPS Publications; 2006. p. 503–54.Google Scholar
  5. Fujishiro K, Hagihara M, Takahashi A, Nagatsu T. Concentrations of neopterin and biopterin in the cerebrospinal fluid of patients with Parkinson’s disease. Biochem Med Metab Biol. 1990;44(2):97–100.View ArticlePubMedGoogle Scholar
  6. Neville BG, Parascandalo R, Farrugia R, Felice A. Sepiapterin reductase deficiency: a congenital dopa-responsive motor and cognitive disorder. Brain. 2005;128(Pt 10):2291–6.View ArticlePubMedGoogle Scholar
  7. Botto LD, Yang Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am J Epidemiol. 2000;151(9):862–77.View ArticlePubMedGoogle Scholar
  8. Kuhn W, Roebroek R, Blom H, et al. Elevated plasma levels of homocysteine in Parkinson’s disease. Eur Neurol. 1998;40(4):225–7.View ArticlePubMedGoogle Scholar
  9. Kaufman S. Some metabolic relationships between biopterin and folate: implications for the “methyl trap hypothesis”. Neurochem Res. 1991;16(9):1031–6.View ArticlePubMedGoogle Scholar
  10. Bezzina Wettinger S, Balim Z, Felice A. Allele frequencies of selected polymorphisms related to thrombosis in the Maltese population. Abstract no 4089 Abstracts for the 42nd annual meeting of American society of Heamatology Blood 96 Part 2 94b. 2000.Google Scholar
  11. Al-Ashtar, A.A. A, J., Bezzina Wettinger S, et al. Case–control study of Libyan and Maltese Patients with Type II Diabetes Mellitus. Eur J Human Genet. 2007;15(5) (Suppl.1). P1148.Google Scholar
  12. Dick FD, De Palma G, Ahmadi A, et al. Gene-environment interactions in parkinsonism and Parkinson’s disease: the Geoparkinson study. Occup Environ Med. 2007;64(10):673–80.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Dick FD, De Palma G, Ahmadi A, et al. Environmental risk factors for Parkinson’s disease and parkinsonism: the Geoparkinson study. Occup Environ Med. 2007;64(10):666–72.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Skibola CF, Smith MT, Kane E, et al. Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci U S A. 1999;96(22):12810–5.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Punia S, Behari M, Govindappa ST, et al. Absence/rarity of commonly reported LRRK2 mutations in Indian Parkinson’s disease patients. NeurosciLett. 2006;409(2):83–8.Google Scholar
  16. Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron. 2004;44(4):595–600.View ArticlePubMedGoogle Scholar
  17. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science. 1997;276(5321):2045–7.View ArticlePubMedGoogle Scholar
  18. Rudd MF, Sellick GS, Allinson R, Matutes E, Catovsky D, Houlston RS. MTHFR polymorphisms and risk of chronic lymphocytic leukemia. Cancer Epidemiol Biomarkers Prev. 2004;13(12):2268–70.PubMedGoogle Scholar
  19. Gomez-Suaga P, Fdez E, Blanca Ramirez M, Hilfiker S. A link between autophagy and the pathophysiology of LRRK2 in Parkinson’s disease. Parkinsons Dis. 2012;2012:324521.PubMedPubMed CentralGoogle Scholar
  20. Kumari U, Tan EK. LRRK2 in Parkinson’s disease: genetic and clinical studies from patients. FEBS J. 2009;276:6455–63.View ArticlePubMedGoogle Scholar
  21. Healy DG, Falchi M, O’Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case–control study. Lancet Neurol. 2008;7(7):583–90.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Zabetian CP, Hutter CM, Yearout D, et al. LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago. Am J Hum Genet. 2006;79(4):752–8.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Mata IF, Taylor JP, Kachergus J, et al. LRRK2 R1441G in Spanish patients with Parkinson’s disease. NeurosciLett. 2005;382(3):309–11.Google Scholar
  24. Spira PJ, Sharpe DM, Halliday G, Cavanagh J, Nicholson GA. Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Ann Neurol. 2001;49(3):313–9.View ArticlePubMedGoogle Scholar
  25. Markopoulou K, Wszolek ZK, Pfeiffer RF, Chase BA. Reduced expression of the G209A alpha-synuclein allele in familial Parkinsonism. AnnNeurol. 1999;46(3):374–81.Google Scholar
  26. Berg D, Niwar M, Maass S, et al. Alpha-synuclein and Parkinson’s disease: implications from the screening of more than 1,900 patients. Mov Disord. 2005;20(9):1191–4.View ArticlePubMedGoogle Scholar
  27. Vidal C, Brincat M, Xuereb-Anastasi A. Effects of polymorphisms in the collagen type 1α1 gene promoter and the C677T variant in the methylenetetrahydrofolate reductase gene on bone mineral density in postmenopausal women in Malta. Balkan J Med Genet. 2007;10:9–18.Google Scholar
  28. Religa D, Czyzewski K, Styczynska M, et al. Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson’s disease. NeurosciLett. 2006;404(1–2):56–60.Google Scholar
  29. Todorovic Z, Dzoljic E, Novakovic I, et al. Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson’s disease, with and without levodopa therapy. JNeurolSci. 2006;248(1–2):56–61.Google Scholar
  30. Jacques PF, Bostom AG, Williams RR, et al. Relation Between Folate Status, a Common Mutation in Methylenetetrahydrofolate Reductase, and Plasma Homocysteine Concentrations. Circulation. 1996;93:7–9.View ArticlePubMedGoogle Scholar
  31. Chen H, Zhang SM, Schwarzschild MA, et al. Folate intake and risk of Parkinson’s disease. Am J Epidemiol. 2004;160(4):368–75.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2016

Advertisement